Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET
Company Participants
Daniel Kontoh-Boateng – DKB Partners
Matt D’Onofrio – Chief Executive Officer
Chris Quesenberry – Chief Commercial Officer, GIMOTI, EVERSANA
Mark Kowieski – Chief Financial Officer
Conference Call Participants
Yale Jen – Laidlaw & Company
Operator
Good afternoon, and welcome to the Evoke Pharma Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently all callers have been placed in a listen-only mode and following management’s prepared remarks, the call will be opened for your questions. [Operator Instructions] Please be advised that today’s call is being recorded. We will be standing by if you should need any assistance.
I would now like to turn the call over to Daniel Kontoh-Boateng. Thank you, sir. You may begin.
Daniel Kontoh-Boateng
Good afternoon and thank you for participating in Evoke Pharma’s conference call today. With me today are Matt D’Onofrio, Evoke’s Chief Executive Officer; Chris Quesenberry, GIMOTI’s Chief Commercial Officer from EVERSANA; and Mark Kowieski, Evoke’s Chief Financial Officer.
By now, you should have a copy of the press release we issued earlier. If not, it is available on the Investor Relations page of our website at evokepharma.com. We encourage everyone to read today’s press release as well as Evoke’s annual report on Form 10-K, which is now filed with the SEC. The company’s Form 10-K and earnings release are also available on Evoke’s website. Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act.
We caution listeners that, during this call, management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company’s business. These forward-looking statements are qualified
Read the full article here